Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. - Wikidata - awgldk - TriplyDB

Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

http://www.wikidata.org/entity/Q43048172

about

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients Cytotoxic and targeted therapy for hereditary cancers Marine Invertebrate Metabolites with Anticancer Activities: Solutions to the "Supply Problem"Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives Emerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities for an innovative approach Trabectedin and plitidepsin: drugs from the sea that strike the tumor microenvironment Pegylated liposomal doxorubicin in the management of ovarian cancer: a systematic review and metaanalysis of randomized trials Treatment options in recurrent ovarian cancer: latest evidence and clinical potential.Bevacizumab in ovarian cancer: A critical review of phase III studies Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy Development of nanoscale approaches for ovarian cancer therapeutics and diagnostics New developments in treatment of ovarian carcinoma: focus on trabectedin A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study.Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours.A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study.Therapeutic strategies for targeting the ovarian tumor stroma.Effect of the Combination of Trabectedin and Pegylated Liposomal Doxorubicin in a BRCA2 Mutation Carrier with Recurrent Platinum-Sensitive Ovarian Cancer.Combination of irinotecan and platinum for platinum-resistant or refractory recurrent ovarian cancers: A preliminary case series.Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence.Overview of a chemoresponse assay in ovarian cancer Chemotherapy: A new standard combination for recurrent ovarian cancer?4-Methylumbelliferone inhibits ovarian cancer growth by suppressing thymidine phosphorylase expression Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval.Major clinical research advances in gynecologic cancer in 2010 Trabectedin: safety and efficacy in the treatment of advanced sarcoma Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104).Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies.Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer A comprehensive safety evaluation of trabectedin and drug-drug interactions of trabectedin-based combinations.Efficacy of trabectedin in metastatic solitary fibrous tumor.Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer.Cost Effectiveness of Chemotherapeutic Agents and Targeted Biologics in Ovarian Cancer: A Systematic Review.Effect of trabectedin on the QT interval in patients with advanced solid tumor malignancies Therapeutic strategies in epithelial ovarian cancer.Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary.

P2860

Q24201282-3CC7C988-744A-42F3-A347-2C0DAE93D66F Q24633820-94222565-682E-4082-8244-43B2B6AFA945 Q26739366-41E732C6-250A-4326-83EF-907FF4DF67A6 Q26746924-4121B447-96F0-4B24-A053-E05571419AD8 Q26749280-A827CF1A-31FC-4320-BC60-88567BE81700 Q26849477-41ED573F-5CB4-408D-8EE2-5AE07EEBCAAA Q26851658-4DBB7ED9-96D7-4594-BC37-FC0079DB14D3 Q26858830-040FDDE5-08A3-4A29-9199-59EC181E0E34 Q27692699-90436835-BEF2-45C9-8F5A-BC41B5A3904E Q28076188-69ED2422-5914-45A8-88DD-A660761B89FF Q28083801-815D0FAF-89B8-4DD3-B54A-A6F6CFB74B0A Q30275792-C2B3191B-6459-44A2-80B2-F27A694B0D6D Q30421664-FF34E1E3-5704-474D-B23B-E44D5E2BB2C6 Q33393429-F9FDC77F-B364-45CB-ABAD-7C186FF1811C Q33397625-329F7617-55C2-4381-9558-3172E8DAB8AA Q33416440-431DB630-8EDC-4791-8F13-2DFF4810B6CC Q33608191-703059B1-F140-4087-A909-57BD381BA970 Q33770035-3CCA17C0-CCDD-4BE5-970B-6297A52280D9 Q33801643-FE2CBE6E-D9E0-4691-ACBA-AC4985185AE2 Q33858199-F4B923FF-631B-4AAB-87EF-6FE1122B505F Q33921802-B37784E8-E9EC-4C22-903A-17C8E23F67ED Q34071625-E76B8FC3-A89C-460E-AF50-9A9E1D9A83E7 Q34206001-1C83C8ED-437A-40FD-9B48-A5F9D01F4AE2 Q34346660-28D2B03A-214C-41D1-8572-8904FB669764 Q34413664-65FB9372-CD5C-4155-A506-B05DB893A043 Q34413670-FB2F928F-1D88-47C2-97FB-576D5E1DDC2F Q34517694-C5C43EFA-E818-40DC-8758-94E8F1674099 Q34628607-0D40736D-2B16-4FC5-BBAC-BB8AC3EA47D8 Q34650482-4DD8D481-FA82-4758-A054-73B8A6FB7890 Q34996149-71A77E16-611F-4C4D-9B6B-563EB5FB8B1F Q35088311-0AFD618D-E31F-4133-9770-F8AD05F80B69 Q35114915-9F9A5525-4A21-4413-B75B-0D0A6D1581E1 Q35246995-CD84AC26-9108-4C0E-B7FD-1B4444B497FD Q35526830-5A4CA03E-9CEA-4E7B-98E3-336E841CCF36 Q35527133-1035BE1F-C836-4161-9D9F-A6E1E544A413 Q35662929-AD417015-466F-4D43-B7BF-F775F8D2D5D9 Q35693620-295CEC84-E882-45FE-B1D7-62826EEEDACC Q35845484-686FC6DC-9D98-4F1B-8AF6-196AA6AA9532 Q35896426-F27A5B75-0E86-4FC3-A35A-1A18167163CE Q35960779-17186671-F90C-4726-A91B-5D43210575BD

P2860

Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

http://www.wikidata.org/entity/Q43048172

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

@en

Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

@nl

type

label

Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

@en

Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

@nl

prefLabel

Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

@en

Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

@nl

P1433

Q43048172-12E92193-F6A4-42B3-9C31-4F6DD1766B53

P1476

Q43048172-1E1AD060-B823-4D0E-853B-3F578EC5694A

P2093

Q43048172-139D14FE-CA05-405F-A03E-F1BB35737E23

Q43048172-1E87D4EB-389E-4A1A-A9C7-D16C0EA95F5B

Q43048172-2F9682C6-C9C3-4466-A919-36A10DEFB932

Q43048172-40C05E98-CE90-46EB-8657-8F609E37CBC6

Q43048172-4F22C7FF-191B-4C35-89D0-1E5E7B5FA07C

Q43048172-5B93B2B7-6E48-4F2F-976C-8AD966B7B4C9

Q43048172-5C925CC6-FF2D-49EE-95AC-E845C24E9DD1

Q43048172-6D7FF3B0-A7DF-44AC-A16C-229EBEDEE154

Q43048172-732D3BFF-1BDB-4F05-B879-6ACF0E55E8D1

Q43048172-7E5FC653-D20B-47B1-AB4E-B0FE4A7F3969

P304

Q43048172-93C61CAD-0DEC-4153-BCD6-74F8CB8A9DC3

P31

Q43048172-8721D811-9A01-474D-939E-CB40CD7E6F1F

P356

Q43048172-26301BB5-E2A9-4F22-929E-66C570FBC2AE

P407

Q43048172-CBA5EB69-D27D-4A7A-8699-24A83F80B0AD

P433

Q43048172-39E9E2D4-3B81-4066-8BF2-19E63E8356AF

P478

Q43048172-4221B44F-4E65-413A-A389-1C53D2946F5A

P50

Q43048172-0D71FBAB-505C-417A-A229-B539AA62B198

Q43048172-3F9E42EC-BFAA-4BA8-87B4-3B9637BC089B

P577

Q43048172-20861FC1-B6D4-412B-AFFA-10313DFC86A5

P698

Q43048172-8ED02142-4016-4F12-B950-23E31EB64228

P921

Q43048172-C25E16A6-F6A5-4D91-BF92-13FB6D036A92

P356

JCO.2009.25.4037

P1433

Journal of Clinical Oncology

P1476

Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer

@en

P2093

Alla S Lisyanskaya

http://www.w3.org/2001/XMLSchema#string

Anatoly N Makhson

http://www.w3.org/2001/XMLSchema#string

Andrés M Poveda

http://www.w3.org/2001/XMLSchema#string

Bradley J Monk

http://www.w3.org/2001/XMLSchema#string

Carolyn N Krasner

http://www.w3.org/2001/XMLSchema#string

Claudia A Lebedinsky

http://www.w3.org/2001/XMLSchema#string

Eric Pujade-Lauraine

http://www.w3.org/2001/XMLSchema#string

Ignace B Vergote

http://www.w3.org/2001/XMLSchema#string

Jan B Vermorken

http://www.w3.org/2001/XMLSchema#string

Janusz Rolski

http://www.w3.org/2001/XMLSchema#string

P304

3107-3114

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2009.25.4037

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Hextan Y S Ngan

P577

2010-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20516432

http://www.w3.org/2001/XMLSchema#string

P921